Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 20/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 20/20 | 0.66 |
| ▸ | RXRA | P19793 | 19/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20988374 | 0.81 | RXRA (0.56) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL20561006 | 0.79 | RXRA (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19211294 | 0.79 | RXRA (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL28604844 | 0.79 | RXRA (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19219180 | 0.79 | GRIN1 (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19211364 | 0.73 | GRIN1 (0.57) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL17502279 | 0.73 | RXRA (0.64) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19219186 | 0.72 | GRIN1 (1.00) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19211355 | 0.72 | RXRA (0.69) | GRIN1GRIN2BRXRAKCNH2 | |
| SCHEMBL19211356 | 0.72 | RXRA (0.69) | GRIN1GRIN2BRXRAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | disclosed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | GRIN1 3/4885GRIN2B 4/4885RXRA 2100/4885 |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | GRIN1 3/4885GRIN2B 4/4885RXRA 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.